Determinants and Long-Term Outcomes of Percutaneous Coronary Interventions vs. Surgery for Multivessel Disease According to Clinical Presentation

Sung-Jin Hong, MD; Byong-Keuk Kim, MD; Sanghoon Shin, MD; Yongsung Suh, MD; Seunghwan Kim, MD; Chul-Min Ahn, MD; Jung-Sun Kim, MD; Young-Guk Ko, MD; Donghoon Choi, MD; Myeong-Ki Hong, MD; Yangsoo Jang, MD

Background: The long-term outcome of percutaneous coronary intervention (PCI) vs. coronary artery bypass graft (CABG), particularly for patients with non-ST-elevation acute coronary syndrome (NSTE-ACS), remains controversial.

Methods and Results: We retrospectively analyzed 2,827 patients (stable coronary artery disease [SCAD], n=1,601; NSTE-ACS, n=1,226) who underwent either PCI (n=1,732) or CABG (n=1,095). The 8-year composite of cardiac death and myocardial infarction (MI) was compared between PCI and CABG before and after propensity matching. For patients with NSTE-ACS, PCI was performed more frequently for those with higher Thrombolysis in Myocardial Infarction risk score and 3-vessel disease, and PCI led to significantly higher 8-year composite of cardiac death and MI than CABG (14.1% vs. 5.9%, hazard ratio [HR]=2.22, 95% confidence interval [CI]=1.37–3.58, P=0.001). There was a significant interaction between clinical presentation and revascularization strategy (P-interaction=0.001). However, after matching, the benefit of CABG vs. PCI was attenuated in patients with NSTE-ACS, whereas it was pronounced in those with SCAD. Interactions between clinical presentation and revascularization strategy were not observed (P-interaction=0.574).

Conclusions: Although the determinants of PCI vs. CABG in real-world clinical practice differ according to the clinical presentation, a significant interaction between clinical presentation and revascularization strategy was not noted for long-term outcomes. The revascularization strategy for patients with NSTE-ACS can be based on the criteria applied to patients with SCAD.

Key Words: Coronary artery bypass graft; Percutaneous coronary intervention
underwent myocardial revascularization with PCI or CABG because of multivessel disease were initially identified from the participating centers in the Korean Multicenter Angioplasty Team (KOMATE) registry. Briefly, the KOMATE registry was designed for enrolling patients who underwent PCI at several centers in Korea and was based on real-world clinical practice. Demographic, clinical, procedural and clinical outcome data were collected retrospectively using case report forms. The Institutional Review Board at the Severance Hospital of the Yonsei University Health System approved this study and waived the requirements for informed consent for this retrospective analysis.

Patients who had the following angiographic findings were defined as having multivessel disease requiring revascularization: patients with ≥2 lesions with >70% diameter stenosis in native coronary arteries with involvement of both the right and left coronary arteries (left anterior descending or circumflex) on quantitative coronary angiography, or those with coexistence of both protected and unprotected left main disease (>50% diameter stenosis). NSTE-ACS was defined as unstable angina and non-ST-segment elevation myocardial infarction (MI).2 In the present study, patients with cardiogenic shock or ST-elevation MI were excluded. Patients whose revascularization was delayed for 2 weeks after diagnostic angiography were also excluded. Among the 2,827 patients, a total of 1,732 patients who underwent PCI, and their data regarding demographic, procedural and clinical outcomes, were identified from the KOMATE registry database. The other 1,095 patients underwent CABG, and their data were collected from medical record reviews.

### Follow-up and Study Endpoints

Clinical assessments were recorded in the hospital after revascularization by either PCI or CABG, and at 1 month, 6 months, and 1, 2, 4, and 8 years after discharge. Follow-up assessments were performed during clinic visits. All-cause death, cardiac death, MI, any revascularization, and stroke were assessed as the clinical outcomes. Also, a composite of cardiac death and MI was assessed as a hard clinical outcome. Clinical events were defined according to the Academic Research Consortium and an expert consensus document that defined the Third Universal Definition for Myocardial Infarction. All deaths were considered cardiac related unless an unequivocal non-cardiac cause could be established. After discharge, MI was defined according to the following parameters: presence of clinical symptoms, ECG changes, or abnormal imaging findings indicative of MI, and an increase in the creatine kinase myocardial band fraction above the upper normal limit or an increase in troponin-T/troponin-I above the 99th percentile of the upper normal limit. Any revascularization was defined as repeat PCI or CABG of both target lesion and non-target lesion because of either (1) angiographic diameter stenosis ≥50% according to quantitative coronary angiographic analysis with documentation of a positive stress test, or (2) angiographic diameter stenosis ≥70% irrespective of the stress test results. Stroke, as detected by the occurrence of a new neurological deficit, was confirmed using a neurological examination and imaging studies.

### Statistical Analysis

Categorical variables are reported as numbers and percentages, and compared by χ² test or Fisher exact test. Continuous variables are reported as mean±standard deviation and compared with Student’s t-test. To reduce treatment selection bias and potential confounding factors, and to adjust for significant differences in the characteristics of patients or lesions, propensity score-matching was performed. Propensity scores were estimated using a nonparamimonious multiple logistic regression model for treatment

### Table 1. Baseline Characteristics of the Study Patients With Stable Coronary Artery Disease

|                     | PCI (n=1,041) | CABG (n=560) | P value | PCI (n=544) | CABG (n=544) | Std mean difference |
|---------------------|--------------|--------------|---------|-------------|--------------|--------------------|
| Age, years          | 65±9         | 64±9         | 0.205   | 65±10       | 65±9         | 0.065             |
| Men                 | 713 (69)     | 411 (73)     | 0.041   | 382 (70)    | 397 (73)     | 0.105             |
| BMI, kg/m²          | 24.8±3.1     | 24.4±2.8     | 0.014   | 24.5±3.2    | 24.5±2.8     | 0.125             |
| Hypertension        | 721 (69)     | 404 (72)     | 0.229   | 383 (70)    | 391 (72)     | −0.062            |
| Diabetes            | 402 (39)     | 234 (42)     | 0.217   | 213 (39)    | 224 (41)     | −0.065            |
| Dyslipidemia        | 680 (65)     | 336 (60)     | 0.035   | 335 (62)    | 330 (61)     | 0.112             |
| Current smoker      | 192 (18)     | 101 (18)     | 0.840   | 98 (18)     | 99 (18)      | 0.011             |
| Previous MI         | 102 (10)     | 71 (13)      | 0.077   | 60 (11)     | 64 (12)      | −0.097            |
| Previous PCI        | 230 (22)     | 104 (19)     | 0.098   | 111 (20)    | 102 (19)     | 0.085             |
| CKD                 | 43 (4)       | 42 (8)       | 0.004   | 35 (6)      | 38 (7)       | −0.169            |
| LVEF, %             | 60±11        | 58±13        | 0.001   | 59±13       | 59±12        | 0.193             |
| 3-vessel disease    | 700 (67)     | 434 (78)     | <0.001  | 401 (74)    | 426 (78)     | −0.059            |
| Left main           | 242 (23)     | 162 (29)     | 0.013   | 139 (26)    | 156 (29)     | −0.134            |
| Proximal LAD        | 760 (73)     | 412 (74)     | 0.808   | 411 (76)    | 405 (74)     | −0.013            |
| LAD, mid and distal | 828 (80)     | 420 (75)     | 0.037   | 421 (77)    | 413 (76)     | 0.112             |
| LCX                 | 842 (81)     | 483 (86)     | 0.007   | 464 (85)    | 473 (87)     | −0.136            |
| RCA                 | 853 (82)     | 476 (85)     | 0.120   | 466 (86)    | 466 (86)     | −0.079            |

Data are presented as mean±SD or n (%). BMI, body mass index; CABG, coronary artery bypass graft; CKD, chronic kidney disease; LAD, left anterior descending; LCX, left circumflex artery; LVEF, left ventricular ejection fraction; MI, myocardial infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery.
with PCI vs. CABG for patients with SCAD and for those with NSTE-ACS. For SCAD, all the clinical and angiographic variables shown in Table 1 were entered to calculate the propensity score. Similarly, for NSTE-ACS, all the variables shown in Table 2 were entered. New propensity scores were incorporated to assess the efficacy of CABG. For the development of propensity score-matched pairs without replacement (1:1 match), a local optimal algorithm was used. The Hansen and Bowers method was used. The baseline characteristics of patients undergoing PCI vs. CABG were presented for those with SCAD and for those with NSTE-ACS in Table 1. Among patients with SCAD in Table 2, 1094 (86%) underwent PCI vs. 190 (24%) for patients with SCAD and for those with NSTE-ACS in Table 2. Among patients with NSTE-ACS (n=1,226), 476 (39%) had acute MI and 691 (56.4%) underwent PCI. For CABG-treated patients, timing from diagnostic angiography to CABG is presented in Figure S1. CABG was performed in 4.2±3.3 days after diagnostic angiography for patients with SCAD, and in 3.8±3.3 days for those with NSTE-ACS. For PCI-treated patients, timing from diagnostic angiography to PCI was significantly shorter than for CABG-treated patients for both patients with SCAD (0.1±0.1 days, P<0.001) and those with NSTE-ACS (0.1±0.1 days, P<0.001). The European System for Cardiac Operative Risk Evaluation (EuroSCORE) II was not different between groups for patients with SCAD (PCI vs. CABG; 1.0±0.8% vs. 1.1±1.1%, P=0.093), or for those with NSTE-ACS (1.2±1.0% vs. 1.3±1.1%, P=0.077). After propensity score-matching for the clinical and angiographic findings, 544 matched pairs were created because of the relatively much greater differences between the PCI- and CABG-treated patients. All variables were well balanced for patients with SCAD and those with NSTE-ACS (Figure S2).

The independent determinants of PCI vs. CABG were different for patients with SCAD and those with NSTE-ACS (Figure 1). For patients with SCAD, PCI treatment was performed less frequently for those with more severe CAD such as 3-vessel disease (adjusted odds ratio [aOR]=0.44, 95% confidence interval [CI]=0.31–0.64, P<0.001). By contrast, for patients with NSTE-ACS, PCI treatment was performed more frequently for those with the same severity of CAD (aOR=3.88, 95% CI=2.25–6.67, P<0.001). The other independent determinants of PCI vs. CABG for SCAD were greater body mass index, previous PCI, absence of chronic kidney disease, no involvement of a left main lesion, and involvement of a mid to distal left main lesion.

### Results

The baseline characteristics of patients undergoing PCI vs. those undergoing CABG are presented for those with SCAD in Table 1 and for NSTE-ACS in Table 2. Among patients with NSTE-ACS (n=1,226), 476 (39%) had acute MI and 691 (56.4%) underwent PCI. For CABG-treated patients, timing from diagnostic angiography to CABG is presented in Figure S1. CABG was performed in 4.2±3.3 days after diagnostic angiography for patients with SCAD, and in 3.8±3.3 days for those with NSTE-ACS. For PCI-treated patients, timing from diagnostic angiography to PCI was significantly shorter than for CABG-treated patients for both patients with SCAD (0.1±0.1 days, P<0.001) and those with NSTE-ACS (0.1±0.1 days, P<0.001). The European System for Cardiac Operative Risk Evaluation (EuroSCORE) II was not different between groups for patients with SCAD (PCI vs. CABG; 1.0±0.8% vs. 1.1±1.1%, P=0.093), or for those with NSTE-ACS (1.2±1.0% vs. 1.3±1.1%, P=0.077). After propensity score-matching for the clinical and angiographic findings, 544 matched pairs were created because of the relatively much greater differences between the PCI- and CABG-treated patients. All variables were well balanced for patients with SCAD and those with NSTE-ACS (Figure S2).

### Table 2. Baseline Characteristics of the Study Patients With Non-ST-Elevation Acute Coronary Syndrome

|                      | PCI (n=691) | CABG (n=535) | P value | PCI (n=287) | CABG (n=287) | Std mean difference |
|----------------------|------------|--------------|---------|------------|--------------|---------------------|
| Age, years           | 64.8±10.8  | 64.9±9.2     | 0.883   | 64.8±11.1  | 64.9±8.9     | −0.003              |
| Men                  | 462 (67)   | 377 (71)     | 0.178   | 199 (69)   | 206 (72)     | 0.052               |
| BMI, kg/m²           | 24.6±3.2   | 24.3±3.0     | 0.094   | 24.6±3.2   | 24.5±3.0     | 0.019               |
| Hypertension         | 477 (69)   | 358 (67)     | 0.431   | 203 (71)   | 201 (70)     | 0.015               |
| Diabetes             | 258 (37)   | 241 (45)     | 0.006   | 127 (44)   | 121 (42)     | 0.043               |
| Dyslipidemia         | 411 (60)   | 300 (56)     | 0.231   | 174 (61)   | 172 (60)     | 0.014               |
| Current smoker       | 203 (29)   | 140 (26)     | 0.214   | 76 (27)    | 82 (29)      | −0.046              |
| Previous MI          | 72 (10)    | 72 (14)      | 0.101   | 47 (16)    | 43 (15)      | 0.046               |
| Previous PCI         | 165 (24)   | 114 (21)     | 0.287   | 79 (28)    | 78 (27)      | 0.008               |
| CKD                  | 54 (8)     | 47 (9)       | 0.540   | 25 (9)     | 22 (8)       | 0.039               |

Clinical presentation

|                      | Before matching | After matching |
|----------------------|-----------------|----------------|
| Unstable angina      | 422 (61)        | 328 (61)       | 0.540   | 25 (9)     | 22 (8)       | 0.039               |
| NSTEMI               | 269 (39)        | 207 (39)       | 0.000   | 181 (63)   | 192 (67)     | 0.079               |
| TIMI risk score      | 3.82±1.12       | 3.06±1.13      | <0.001  | 3.65±1.10  | 3.40±1.10    | 0.218               |
| LVEF, %              | 56.4±12.6       | 52.5±14.1      | <0.001  | 55.2±13.4  | 55.2±13.3    | −0.001              |
| 3-vessel disease     | 488 (71)        | 352 (66)       | <0.001  | 186 (65)   | 210 (73)     | −0.082              |
| Left main            | 144 (21)        | 163 (31)       | <0.001  | 88 (24)    | 71 (25)      | −0.026              |
| Proximal LAD         | 502 (73)        | 277 (52)       | <0.001  | 192 (67)   | 197 (69)     | 0.039               |
| LAD, mid and distal  | 542 (78)        | 262 (49)       | <0.001  | 199 (69)   | 202 (70)     | −0.025              |
| LCX                  | 569 (82)        | 338 (63)       | <0.001  | 228 (79)   | 234 (82)     | −0.055              |
| RCA                  | 597 (86)        | 348 (65)       | <0.001  | 238 (83)   | 238 (83)     | 0.000               |

Data are presented as mean±SD or n (%). NSTEMI, non-ST-elevation myocardial infarction; TIMI, Thrombolysis in Myocardial Infarction. Other abbreviations as in Table 1.
PCI vs. CABG

For patients with NSTE-ACS, the independent predictors of PCI vs. CABG were absence of diabetes, higher Thrombolysis in Myocardial Infarction (TIMI) risk score, greater left ventricular ejection fraction, and involvement of a left anterior descending artery, left circumflex artery, and right coronary artery lesion (Figure 1).

With a median follow-up of 6.8 years (interquartile range, 5.1–8.3 years), the clinical outcomes at 4 and 8 years are summarized in Table 3 for patients with SCAD, and in Table 4 for those with NSTE-ACS. For patients with SCAD, those treated with PCI experienced a significantly higher composite endpoint of cardiac death and MI vs. those treated with CABG at 4 years (2.8% vs. 0.7%, hazard ratio [HR]=4.54, 95% CI=1.38–14.90, P=0.006), mainly driven by higher rates of MI (2.1% vs. 0.5%, HR=4.88, 95% CI=1.14–20.80, P=0.018). However, at 8 years, these differences had decreased without statistical significance (5.5% vs. 3.6%, HR=1.67, 95% CI=0.90–3.10, P=0.100) (Figure 2A). After propensity score-matching, these findings were again more pronounced in patients with SCAD, with a borderline statistical significance (Figure 2B). Patients treated with PCI had significantly higher rate of repeat revascularizations compared with those treated with CABG (30.4% vs. 12.7%, HR=2.76, 95% CI=2.03–3.77, P<0.001) (Figure 2G). As for the revascularization strategy for repeat revascularization, 11.8% (29/246) among the PCI group were treated with CABG, and 6.3% (3/48) among the CABG group were treated with CABG.

For patients with NSTE-ACS, the rate of the composite of cardiac death and MI at 8 years was significantly higher in PCI-treated patients than in CABG-treated patients (14.1% vs. 5.9%, HR=2.22, 95% CI=1.37–3.58, P=0.001) (Figure 3A), mainly driven by a higher rate of MI in PCI-treated patients (12.3% vs. 3.9%, HR=3.45, 95% CI=1.85–6.42, P<0.001) (Figure 3E). However, after matching the clinical and angiographic findings (287 matched pairs), these differences were attenuated for composite of cardiac death and MI (9.7% vs. 6.8%, HR=1.46, 95% CI=0.75–2.86, P=0.264) (Figure 3B) and MI (7.2% vs. 3.7%, HR=2.13, 95% CI=0.88–5.19, P=0.088) (Figure 3F). Similar to the patients with SCAD, patients treated with PCI had significantly higher rate of repeat revascularizations compared with those treated with CABG; 11.5% (20/173) among the PCI group were treated with CABG, and 7.3% (4/55) among the CABG group were treated with CABG.

Although there was a significant interaction between clinical presentation (SCAD vs. NSTE-ACS) and revascularization strategy (PCI vs. CABG) for an 8-year composite of cardiac death and MI before matching (P-interaction=0.001), significant interactions were not observed after matching (P-interaction=0.574).
### Table 3. Clinical Outcomes for the Study Patients With Stable Coronary Artery Disease

|                      | Before matching | After matching |
|----------------------|-----------------|----------------|
|                      | PCI (n=1,041)    | CABG (n=560)   | HR (95% CI) | P value | PCI (n=544)    | CABG (n=544)   | HR (95% CI) | P value |
| 4-year outcome       |                 |                |            |         |                 |                |            |         |
| Composite of cardiac death and MI | 29 (2.8%)       | 3 (0.7%)       | 4.54       | (1.38–14.90) | 0.006          | 18 (3.4%)      | 3 (0.7%)   | 5.30     | (1.56–17.99) | 0.003 |
| Death                | 26 (2.5%)       | 15 (3.2%)      | 0.80       | (0.42–1.51)  | 0.491          | 19 (3.6%)      | 15 (3.2%)  | 1.11     | (0.56–2.18)  | 0.770 |
| Cardiac death        | 12 (1.2%)       | 1 (0.2%)       | 5.68       | (0.74–43.71) | 0.059          | 10 (1.9%)      | 1 (0.2%)   | 8.91     | (1.14–69.65) | 0.012 |
| MI                   | 21 (2.1%)       | 2 (0.5%)       | 4.88       | (1.14–20.80) | 0.018          | 10 (1.9%)      | 2 (0.5%)   | 4.33     | (0.95–19.78) | 0.039 |
| Any revascularization| 151 (14.9%)     | 19 (3.9%)      | 3.90       | (2.42–6.29)  | <0.001         | 84 (16.1%)     | 19 (4.0%)  | 4.08     | (2.48–6.71)  | <0.001 |
| Stroke               | 27 (2.7%)       | 7 (1.5%)       | 1.78       | (0.77–4.07)  | 0.172          | 18 (3.5%)      | 7 (1.6%)   | 2.25     | (0.94–5.39)  | 0.061 |
| 8-year outcome       |                 |                |            |         |                 |                |            |         |
| Composite of cardiac death and MI | 45 (5.5%)       | 13 (3.6%)      | 1.67       | (0.90–3.10)  | 0.100          | 27 (6.4%)      | 13 (3.7%)  | 1.89     | (0.99–3.67)  | 0.055 |
| Death                | 45 (5.5%)       | 36 (9.3%)      | 0.59       | (0.34–0.92)  | 0.018          | 28 (6.6%)      | 35 (9.2%)  | 0.72     | (0.44–1.18)  | 0.189 |
| Cardiac death        | 14 (1.4%)       | 8 (2.3%)       | 0.81       | (0.34–1.94)  | 0.641          | 11 (2.3%)      | 8 (2.2%)   | 1.21     | (0.49–3.02)  | 0.678 |
| MI                   | 36 (4.7%)       | 7 (1.8%)       | 2.49       | (1.11–5.61)  | 0.022          | 19 (5.0%)      | 7 (1.9%)   | 2.48     | (1.04–5.91)  | 0.034 |
| Any revascularization| 246 (30.4%)     | 48 (12.7%)     | 2.76       | (2.03–3.77)  | <0.001         | 127 (30.8%)    | 46 (12.6%) | 2.82     | (2.01–3.95)  | <0.001 |
| Stroke               | 44 (5.6%)       | 18 (4.9%)      | 1.18       | (0.68–2.04)  | 0.559          | 26 (5.9%)      | 17 (4.7%)  | 1.39     | (0.75–2.57)  | 0.288 |

Data are presented as n (% of the cumulative rates according to Kaplan-Meier event rates). P values are from the log-rank test. CI, confidence interval; HR, hazard ratio. Other abbreviations as in Table 1.

### Table 4. Clinical Outcomes for the Study Patients With Non-ST-Elevation Acute Coronary Syndrome

|                      | Before matching | After matching |
|----------------------|-----------------|----------------|
|                      | PCI (n=691)      | CABG (n=535)   | HR (95% CI) | P value | PCI (n=287)      | CABG (n=287)   | HR (95% CI) | P value |
| 4-year outcome       |                 |                |            |         |                 |                |            |         |
| Composite of cardiac death and MI | 45 (6.8%)       | 15 (3.4%)      | 1.97       | (1.10–3.54) | 0.020          | 15 (5.4%)      | 8 (3.2%)   | 1.70     | (0.72–4.01)  | 0.221 |
| Death                | 47 (6.9%)       | 22 (4.9%)      | 1.38       | (0.83–2.29) | 0.210          | 20 (7.1%)      | 10 (4.0%)  | 1.77     | (0.83–3.79)  | 0.134 |
| Cardiac death        | 16 (2.4%)       | 11 (2.4%)      | 0.94       | (0.44–2.02) | 0.871          | 5 (1.8%)       | 6 (2.4%)   | 0.74     | (0.23–2.44)  | 0.624 |
| MI                   | 35 (5.3%)       | 7 (1.7%)       | 3.30       | (1.46–7.43) | 0.002          | 11 (4.0%)      | 4 (1.7%)   | 2.49     | (0.79–7.83)  | 0.106 |
| Any revascularization| 124 (18.6%)     | 34 (12.5%)     | 2.48       | (1.70–3.62) | <0.001         | 51 (18.6%)     | 19 (7.6%)  | 2.46     | (1.45–4.17)  | 0.001 |
| Stroke               | 10 (1.5%)       | 11 (2.8%)      | 0.56       | (0.24–1.33) | 0.185          | 5 (1.8%)       | 8 (3.6%)   | 0.53     | (0.17–1.63)  | 0.263 |
| 8-year outcome       |                 |                |            |         |                 |                |            |         |
| Composite of cardiac death and MI | 71 (14.1%)     | 22 (5.9%)      | 2.22       | (1.37–3.58) | 0.001          | 22 (9.7%)      | 14 (6.8%)  | 1.46     | (0.75–2.86)  | 0.264 |
| Death                | 70 (12.7%)      | 39 (11.1%)     | 1.19       | (0.81–1.76) | 0.381          | 28 (12.5%)     | 22 (11.2%) | 1.19     | (0.68–2.09)  | 0.540 |
| Cardiac death        | 21 (3.7%)       | 16 (4.6%)      | 0.87       | (0.45–1.66) | 0.665          | 7 (3.0%)       | 10 (5.1%)  | 0.64     | (0.24–1.69)  | 0.367 |
| MI                   | 59 (12.3%)      | 12 (3.9%)      | 3.45       | (1.85–6.42) | <0.001         | 16 (7.2%)      | 7 (3.7%)   | 2.13     | (0.88–5.19)  | 0.088 |
| Any revascularization| 173 (30.5%)     | 55 (14.5%)     | 2.24       | (1.65–3.03) | <0.001         | 75 (35.9%)     | 33 (16.5%) | 2.26     | (1.50–3.41)  | <0.001 |
| Stroke               | 20 (3.9%)       | 22 (6.8%)      | 0.59       | (0.32–1.08) | 0.080          | 10 (4.7%)      | 14 (7.4%)  | 0.64     | (0.29–1.45)  | 0.281 |

Data are presented as n (% of the cumulative rates according to Kaplan-Meier event rates). P values are from the log-rank test. Abbreviations as in Tables 1,3.
PCI vs. CABG

with NSTE-ACS. For patients with SCAD, PCI treatment was performed less often for those with 3-vessel disease or left main lesion involvement. For patients with NSTE-ACS, PCI treatment was performed more frequently for those with higher TIMI risk score and greater incidence of

### Discussion

The principal findings of the present study were as follows.

1. The determinants of PCI vs. CABG for multivessel CAD were different between patients with SCAD and those with NSTE-ACS. For patients with SCAD, PCI treatment was performed less often for those with 3-vessel disease or left main lesion involvement. For patients with NSTE-ACS, PCI treatment was performed more frequently for those with higher TIMI risk score and greater incidence of

**Figure 2.** (A–H) Clinical outcomes for patients with stable coronary artery disease. HR, hazard ratio; MI, myocardial infarction. Other abbreviations as in Figure 1.
3-vessel disease. (2) For patients with NSTE-ACS, those treated with PCI had significantly higher rate of the composite of cardiac death and MI at 8 years than those treated with CABG, mainly driven by MI, although the benefit of CABG vs. PCI was attenuated after matching. By contrast, the benefit of CABG vs. PCI was pronounced in patients with SCAD after matching. Notably, a significant interaction between clinical presentation and revascularization strategy was noted before matching, but not after matching.

Although the current guideline recommends that the choice of PCI or CABG for multivessel CAD needs to be

Figure 3. (A–H) Clinical outcomes for patients with non-ST-elevation acute coronary syndrome. Abbreviations as in Figures 1, 2.
based on the clinical status as well as the severity and distribution of CAD, there are no randomized clinical trials comparing PCI with CABG, particularly for patients with NSTE-ACS. Although not randomized, 2 recent prospective studies reported conflicting results regarding the outcomes between PCI and CABG in patients with NSTE-ACS.\(^6\)\(^7\) According to a post hoc analysis of the ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) trial of 5,627 patients with NSTE-ACS with multivessel CAD, a total of 4,412 (78%) underwent PCI while the remaining patients were treated surgically.\(^6\) After propensity score-matching (528 matched pairs), there were no significant differences between PCI-treated patients and CABG-treated patients in all-cause death (5.7% vs. 4.4%, \(P=0.58\)) and cardiac death (4.7% vs. 3.1%, \(P=0.26\)) at 1 year. PCI-treated patients had higher rates of unplanned revascularization (12.6% vs. 0.2%, \(P<0.0001\)) and tended to more frequently experience major adverse cardiac event (25.0% vs. 19.2%; \(P=0.053\)) at 1 year. In another prospective registry study (from the Milestone Registry), 4,566 patients with NSTE-ACS and multivessel CAD, including left main disease, were analyzed.\(^7\) A total of 3,033 patients were selected for stenting (10.3% received drug-eluting stents) and 1,533 for CABG. For the 929 well-matched pairs after propensity score-matching, the 3-year survival was higher in patients treated with PCI than in those treated with surgery (86% vs. 82%, HR=1.33, \(P=0.01\)). According to those studies, the 1- and 3-year outcomes were comparable between PCI and CABG for patients with NSTE-ACS. In the present study, a longer-term follow-up (8 years) was performed, and comparable outcomes were found between PCI and CABG after matching, although the composite of cardiac death and MI was significantly higher in PCI-treated patients than in CABG-treated patients before matching.

Furthermore, for patients with SCAD, CABG was more beneficial than PCI after matching. Although the benefit of CABG was attenuated, particularly for patients with NSTE-ACS, our finding of the superiority of CABG particularly for multivessel disease was consistent with previous studies. A recent meta-analysis of individual patient data from 3 randomized clinical trials included a total of 3,280 patients with multivessel disease or left main disease.\(^\) Among the patients, 1,282 (39%) presented with NSTE-ACS. The rate of the primary outcome, a composite of all-cause death, MI or stroke, was significantly lower with CABG than with PCI (13.0% vs. 16.0%; \(P=0.046\)).\(^1\) Our findings also support the current guideline recommendation of performing CABG for more severe complex CAD.\(^3\)\(^5\) based on recent randomized trials.\(^13\)\(^16\)

**Study Limitations**

First, the patients were not randomized, although we matched PCI- and CABG-treated patients for SCAD and NSTE-ACS. Second, a detailed anatomic analysis of CAD (i.e., SYNTAX score) was not performed. Third, even though the patients were followed long-term, the number of patients was relatively small. Fourth, particularly for the patients with NSTE-ACS, the timing of revascularization from diagnostic angiography to revascularization might have affected early and long-term results. Although this interaction analysis for the timing of revascularization and the revascularization strategies was not performed in the present study, further studies evaluating the benefit of the faster PCI are required.

In conclusion, the determinants of PCI vs. CABG were different between patients with SCAD and those with NSTE-ACS in real-world clinical practice. For patients with NSTE-ACS, PCI treatment was performed more frequently for those with higher TIMI risk score and greater incidence of 3-vessel disease, which was related to worse outcomes at 8 years. However, after matching, the benefit of CABG vs. PCI was attenuated in patients with NSTE-ACS and there were no significant interactions between the revascularization strategies and clinical presentation for long-term outcomes. Thus, the revascularization strategy for patients with NSTE-ACS can be based on the criteria applied to patients with SCAD.

**Sources of Funding**

This study was supported by a grant from the Korean Society of Interventional Cardiology, Republic of Korea (No. 2015-1), and a grant from the Korea Healthcare Technology Research & Development Project, Ministry for Health & Welfare, Republic of Korea (Nos. A085136 and HI15C1277), the Mid-Career Researcher Program through an NRF grant funded by the MEST, Republic of Korea (No. 2015R1A2A2A01002731), and the Cardiovascular Research Center, Seoul, Republic of Korea.

**Disclosures**

The authors have no conflicts of interest to disclose.

**References**

1. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130:e344–e426.
2. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016;37:267–315.
3. Windecker S, Kopta F, Collet JP, Cremer J, Falk V, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541–2619.
4. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:e574–e651.
5. Collet JP, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG, et al. 2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011;124:e652–e735.
6. Ben-Gal Y, Moses JW, Mehran R, Lansky AJ, Weisz G, Nikolsky E, et al. Surgical versus percutaneous revascularization for multivessel disease in patients with acute coronary syndromes: Analysis from the ACUTY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. JACC Cardiovasc Interv 2010;3:1059–1068.
7. Buszman PE, Buszman PP, Bochenek A, Gierlotka M, Gasior M, Milewski K, et al. Comparison of stenting and surgical revascularization strategy in non-ST elevation acute coronary syndromes and complex coronary artery disease (from the Milestone Registry). Am J Cardiol 2014;114:979–987.
8. Kim JS, Lee BH, Ko YG, Choi D, Jang Y, Min PK, et al. Comparison of sirolimus-eluting stent and paclitaxel-eluting
stent for long-term cardiac adverse events in diabetic patients: The Korean Multicenter Angioplasty Team (KOMATE) Registry. Catheter Cardiovasc Interv 2008; 72: 601 – 607.

9. Kim BK, Oh S, Jeon DW, Yang JY, Kim JS, Park S, et al. Long-term clinical outcomes and stent thrombosis of sirolimus-eluting versus bare metal stents in patients with end-stage renal disease: Results of Korean multicenter angioplasty team (KOMATE) Registry. J Interv Cardiol 2009; 22: 411 – 419.

10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van ES GA, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007; 115: 2344 – 2351.

11. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020 – 2035.

12. Lee CW, Ahn JM, Cavalcante R, Sotomi Y, Onuma Y, Suwannasom P, et al. Coronary artery bypass surgery versus drug-eluting stent implantation for left main or multivessel coronary artery disease: A meta-analysis of individual patient data. JACC Cardiovasc Interv 2016; 9: 2481 – 2489.

13. Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, et al. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med 2009; 360: 961 – 972.

14. Park SJ, Kim YH, Park DW, Yun SC, Ahn JM, Song HG, et al. Randomized trial of stents versus bypass surgery for left main coronary artery disease. N Engl J Med 2011; 364: 1718 – 1727.

15. Park SJ, Ahn JM, Kim YH, Park DW, Yun SC, Lee JY, et al. Trial of everolimus-eluting stents or bypass surgery for coronary disease. N Engl J Med 2015; 372: 1204 – 1212.

16. Farkouh ME, Domanski M, Sleeper LA, Siami FS, Dangas G, Mack M, et al. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med 2012; 367: 2375 – 2384.

Supplementary Files

Supplementary File 1

Figure S1. Timing from diagnostic angiography to surgery for CABG-treated patients.

Figure S2. Love plots for absolute standardized difference for baseline covariate between PCI-treated patients and CABG-treated patients, before and after propensity score-matching.

Please find supplementary file(s);
http://dx.doi.org/10.1253/circj.CJ-17-1173